A Covalent Protein Inhibitor For Sars-Cov-2
Technology Description
This invention introduces a groundbreaking covalent protein inhibitor designed to irreversibly bind to the spike (S) protein of SARS-CoV-2, effectively preventing viral infection. Currently at the proof-of-concept stage, the technology has demonstrated irreversible binding of the inhibitor to the virus in laboratory studies. Unlike existing therapeutic approaches based on the noncovalent binding of ACE2 extracellular domain proteins, this innovation utilizes a novel covalent mechanism, offering “infinite affinity” with zero off-rate. This unique approach ensures complete and long-lasting inhibition of the virus, paving the way for a safe and efficient antiviral drug with potential applications in both prophylaxis and treatment of COVID-19.
Stage of Development
proof-of-concept
Related Materials
Data Availability
Patent Status
| Country | Type | Number | Dated | Case |
| European Patent Office | Published Application | 2020-231 | ||
| Patent Cooperation Treaty | Reference for National Filings | WO2022/232377 | 11/03/2022 | 2020-231 |
Additional Patent Pending
Contact
- Catherine Smith
- Catherine.Smith2@ucsf.edu
- tel: View Phone Number.
